SG Americas Securities LLC Makes New $623,000 Investment in Evolus, Inc. (NASDAQ:EOLS)

SG Americas Securities LLC bought a new stake in Evolus, Inc. (NASDAQ:EOLS - Free Report) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 38,447 shares of the company's stock, valued at approximately $623,000. SG Americas Securities LLC owned about 0.06% of Evolus at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in EOLS. Healthcare of Ontario Pension Plan Trust Fund acquired a new position in shares of Evolus in the second quarter worth about $1,326,000. Quarry LP acquired a new position in shares of Evolus during the second quarter worth approximately $54,000. Algert Global LLC acquired a new position in shares of Evolus during the second quarter worth approximately $210,000. The Manufacturers Life Insurance Company lifted its position in Evolus by 36.3% in the second quarter. The Manufacturers Life Insurance Company now owns 21,825 shares of the company's stock worth $237,000 after purchasing an additional 5,808 shares during the period. Finally, AQR Capital Management LLC lifted its position in Evolus by 33.3% in the second quarter. AQR Capital Management LLC now owns 72,007 shares of the company's stock worth $781,000 after purchasing an additional 17,971 shares during the period. Institutional investors and hedge funds own 90.69% of the company's stock.

Analysts Set New Price Targets

Several analysts have issued reports on EOLS shares. Needham & Company LLC reissued a "buy" rating and set a $22.00 target price on shares of Evolus in a research note on Friday, September 13th. Cantor Fitzgerald restated an "overweight" rating on shares of Evolus in a report on Monday, September 16th. HC Wainwright restated a "buy" rating and set a $27.00 price target on shares of Evolus in a report on Thursday, October 3rd. Finally, Barclays increased their target price on shares of Evolus from $16.00 to $20.00 and gave the company an "overweight" rating in a research note on Friday, September 13th.

Evolus Trading Down 3.1 %

Shares of NASDAQ EOLS traded down $0.54 during midday trading on Tuesday, reaching $16.70. 536,357 shares of the stock were exchanged, compared to its average volume of 585,802. The business has a 50-day simple moving average of $15.57 and a two-hundred day simple moving average of $13.39. The company has a market capitalization of $1.05 billion, a price-to-earnings ratio of -15.90 and a beta of 1.31. Evolus, Inc. has a 12 month low of $7.44 and a 12 month high of $17.82. The company has a debt-to-equity ratio of 6.26, a current ratio of 2.92 and a quick ratio of 2.67.

Evolus (NASDAQ:EOLS - Get Free Report) last issued its quarterly earnings results on Wednesday, July 31st. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.02). The business had revenue of $66.91 million for the quarter, compared to analysts' expectations of $65.06 million. As a group, equities research analysts expect that Evolus, Inc. will post -0.64 EPS for the current year.

Insider Buying and Selling

In other Evolus news, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of the business's stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $15.85, for a total value of $89,251.35. Following the completion of the sale, the chief marketing officer now owns 82,375 shares of the company's stock, valued at $1,305,643.75. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other Evolus news, CFO Sandra Beaver sold 3,276 shares of the company's stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $14.98, for a total value of $49,074.48. Following the completion of the transaction, the chief financial officer now directly owns 148,502 shares in the company, valued at approximately $2,224,559.96. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of Evolus stock in a transaction on Friday, August 30th. The stock was sold at an average price of $15.85, for a total transaction of $89,251.35. Following the transaction, the chief marketing officer now directly owns 82,375 shares of the company's stock, valued at $1,305,643.75. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 6.10% of the stock is currently owned by insiders.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.